Pallas Capital Advisors LLC Makes New $570.75 Million Investment in Bruker Corporation $BRKR

Pallas Capital Advisors LLC acquired a new position in shares of Bruker Corporation (NASDAQ:BRKR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 9,483,978 shares of the medical research company’s stock, valued at approximately $570,746,000. Bruker comprises about 17.6% of Pallas Capital Advisors LLC’s investment portfolio, making the stock its biggest position. Pallas Capital Advisors LLC owned about 0.06% of Bruker as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in BRKR. Los Angeles Capital Management LLC acquired a new position in Bruker in the fourth quarter valued at $26,000. Allworth Financial LP boosted its stake in Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares during the last quarter. Essential Partners LLC purchased a new stake in Bruker in the 1st quarter valued at about $36,000. Global Retirement Partners LLC purchased a new stake in Bruker in the 2nd quarter valued at about $38,000. Finally, Parallel Advisors LLC increased its stake in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

BRKR opened at $57.67 on Tuesday. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $65.30. The company has a 50 day moving average of $58.39 and a two-hundred day moving average of $47.11. The company has a market cap of $8.79 billion, a P/E ratio of -82.39, a P/E/G ratio of 1.76 and a beta of 1.28. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 annualized dividend and a yield of 0.3%. Bruker’s dividend payout ratio (DPR) is -28.57%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on BRKR shares. Citigroup decreased their target price on shares of Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research report on Wednesday, August 5th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a research note on Wednesday, August 5th. Finally, Guggenheim upped their price objective on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.64.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.